Moderna, Inc. (MRNA) shares surged 5.05% in pre-market trading on Monday, following a significant announcement from the U.S. Food and Drug Administration (FDA). The regulatory body has granted approval for Moderna's next-generation Covid-19 vaccine, specifically for adults aged 65 and older.
The FDA's decision marks a crucial milestone for Moderna, potentially opening up a substantial market segment for its updated vaccine. This approval comes at a time when health authorities worldwide are focusing on protecting vulnerable populations, particularly older adults, against evolving Covid-19 variants.
This development could have significant implications for Moderna's revenue stream and market position in the competitive vaccine landscape. As the company continues to innovate and adapt its vaccine technology, this FDA approval may strengthen investor confidence in Moderna's long-term growth prospects and its ability to respond to ongoing public health needs.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。